<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743911</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 0044.0.146.000-09</org_study_id>
    <secondary_id>[2009/53430-7]</secondary_id>
    <nct_id>NCT01743911</nct_id>
  </id_info>
  <brief_title>Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients</brief_title>
  <official_title>Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left ventricle diastolic dysfunction (LVDD) is associated with resistant hypertension. In
      addition, brain natriuretic peptide (BNP) levels are elevated when LVDD is present. It has
      been shown that phosphodiesterase-5 (PDE5) inhibition improves left ventricle diastolic
      function in hypertensive rats, despite any difference in blood pressure levels. Also, left
      ventricle diastolic function enhancement reduces BNP concentration in hypertensive patients.
      However, it is unknown if these effects exists in humans with resistant hypertension.
      Therefore, this study was developed to evaluate if the use of a PDE5 inhibitor (tadalafil)
      for 2 weeks improves LVDD and its effects in BNP levels in resistant hypertensive patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resistant hypertensive patients have a high incidence of left ventricle diastolic dysfunction
      (LVDD). Lowering blood pressure levels improves diastolic function, however, there is no
      proved effective treatment specifically for this disease. Studies in hypertensive rats have
      shown presence of phosphodiesterase-5 in cardiac cells and an improvement in left ventricle
      diastolic function using a phosphodiesterase-5 (PDE5) inhibitor, the sildenafil. PDE5 has
      also been demonstrated in human heart cells with cardiac disease. In addition, LVDD is
      associated with high levels of brain natriuretic peptide (BNP), which reduces with diastolic
      function improvement. Therefore, it is reasonable to suppose that PDE-5 inhibitor use in
      humans with LVDD and resistant hypertension could improve diastolic function. Objective:
      Evaluate the chronic effect of a PDE-5 inhibitor on LVDD and BNP levels in resistant
      hypertensive patients. Casuistic and methods: 20 resistant hypertensive patients with LVDD
      types I and II will be evaluated with echocardiography study, ambulatory blood pressure
      monitoring (ABPM), office blood pressure measurements, endothelial function analysis using
      the brachial artery flow mediation dilation technique (FMD) and BNP plasma levels. Then, the
      subjects will receive oral placebo for 2 weeks. After this period, the same exams will be
      repeated. Two weeks later, the protocol will be performed again to the same 20 patients,
      using tadalafil (the longest half-life PDE-5 inhibitor) 20mg orally instead of the placebo.
      Hypothesis: investigators hypothesize that the use of tadalafil will improve left ventricle
      diastolic function with BNP reduced levels and this effect will be independent of blood
      pressure decrease or endothelial function improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricle Diastolic Dysfunction</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Outcome measurement assessed by Echocardiogram before and after a 2-week tadalafil administration period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>Outcome measure assessed by flow-mediated dilation before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Blood pressure measurements assessed before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-type Natriuretic Peptide (BNP-32) levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Plasma brain natriuretic peptide (BNP-32)assessed before and after a 2-week tadalafil administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cyclic guanosine monophosphate (cGMP) levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Cyclic guanosine monophosphate (cGMP) levels assessed before and after a 2-week tadalafil administration period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nitrite levels</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <description>Nitrite levels assessed before and after a 2-week tadalafil administration period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: sugar pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: tadalafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>Sugar pills: 20mg orally, once a day for 2 weeks</description>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>No brand name.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil pills: 20mg orally, once a day for 2 weeks.</description>
    <arm_group_label>tadalafil</arm_group_label>
    <other_name>Cialis, Lilly, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resistant hypertension (according to Resistant Hypertension - American Heart
             Association Statement - 2008);

          -  compliance with antihypertensive treatment;

          -  age &gt;35 years;

          -  left ventricle diastolic dysfunction types I and II

        Exclusion Criteria:

          -  valvulopathy

          -  decompensated heart failure

          -  important cardiac arrhythmias

          -  nephropathy

          -  hepatopathy

          -  autoimmune disease

          -  tabagism

          -  decompensated diabetes

          -  uncontrolled dislipidemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heitor Moreno-Junior, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medical Sciences - Unicamp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Cardiovascular Pharmacology - FCM - Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Heitor Moreno Junior</investigator_full_name>
    <investigator_title>MD, PhD.</investigator_title>
  </responsible_party>
  <keyword>Tadalafil</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Left Ventricle Diastolic Dysfunction</keyword>
  <keyword>Brain natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

